ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma.

Tao XingLi LiXiaosong RaoJing ZhaoYiran ChenGaoda JuYaping XuXuan GaoGuilan DongXuefeng XiaYanfang GuanLingling ZhangZhenping WenJun Liang

Published in: BMC gastroenterology (2024)

To conclude, we have shown that the ARID1A deficiency was correlated with more active immune signatures and higher expression of immune checkpoints in HBV-HCC. Additionally, the present study provides insights to explore the possibility of the predictive role of ARID1A in HBV-HCC patients responsive to immunotherapy.

Keyphrases

hepatitis b virus
liver failure
end stage renal disease
chronic kidney disease
poor prognosis
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
patient reported outcomes
replacement therapy
gene expression
long non coding rna